Summary

In patients with diabetic macular edema, long-term intravitreal injections of ranibizumab maintains best-corrected visual acuity and central retinal subfield thickness improvements over 36 months, with no new or increased safety concerns. This article discusses the final analysis of the 36-month study comprising: A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-Label Extension Study [RESTORE; NCT00687804].